B2i Digital sets Sept. 17 life sciences investor forum

B2i Digital will host a virtual life sciences investor forum on Sept. 17 with live presentations and Q&A from seven public companies across oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics and respiratory imaging. Replays will be posted after the event on the B2i Digital and OTC Markets YouTube channels.

Why it matters: - The forum gives investors direct access to management teams from seven public life sciences companies in one online event. - The lineup covers several high-interest development areas, including cancer, fibrosis, infectious disease, cannabinoid therapeutics and imaging. - The event could help participating companies reach retail and institutional investors through live presentations and Q&A.

What happened: - B2i Digital invited investors to the Life Sciences Virtual Investor Forum, a B2i Digital Featured Conference, set for Thursday, Sept. 17, 2026. - Virtual Investor Conferences is hosting the online event. - B2i Digital is the official marketing partner for the forum. - Event details and company profiles are available here. - Registration is available here.

The details: - The presenting companies, as of Sept. 11, 2026, are subject to change. - The schedule starts at 11:00 a.m. ET with Sona Nanotech Inc. and runs through 4:00 p.m. ET with 4DMedical Ltd. - Raphael Pharmaceutical is set for 11:30 a.m. ET. - Amplia Therapeutics Ltd. is scheduled for 2:00 p.m. ET. - Adaptin Bio, Inc. is scheduled for 2:30 p.m. ET. - Acurx Pharmaceuticals, Inc. is scheduled for 3:00 p.m. ET. - CytoDyn Inc. is scheduled for 3:30 p.m. ET. - 4DMedical Ltd. is scheduled for 4:00 p.m. ET. - The company lineup includes a photothermal cancer therapy built on gold nanorods. - The lineup also includes cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation and autoimmune disease. - Another presenting company is developing precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier. - The forum also features a new class of antibiotics in development for infections caused by bacteria listed as priority pathogens. - One presenter is studying a humanized monoclonal antibody in solid-tumor oncology. - Another company has a pipeline of focal adhesion kinase inhibitors for cancer and fibrosis. - 4DMedical will present FDA-cleared four-dimensional respiratory imaging. - Replays will be available on the B2i Digital and OTC Markets YouTube channels.

Between the lines: - The forum format is built around live management access, which can matter for investors trying to gauge execution, strategy and responsiveness. - The company mix suggests B2i Digital is targeting sectors where clinical milestones and regulatory updates can move stocks. - OTC Markets’ involvement signals the event is aimed at a broad set of public companies, not just large-cap names.

What's next: - The forum will take place online on Sept. 17. - Investors can register in advance and review company profiles before the sessions begin. - B2i Digital said replays will remain available after the live event.

The bottom line: - The Sept. 17 forum is a one-day investor showcase for seven life sciences companies pitching live to market watchers.